MedTrace Logo

Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors

NCT06940349 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-04-23

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if a combination of Palbociclib and Sunitinib is safe and effective in various solid tumors.

The main questions it aims to answer are:

* Is the drugs combination safe for the participants?
* Is the drug combination effective in all solid malignancies? It is a single arm study, phase 1b/2, dose escalation and expansion, to determine the safety, tolerability and initial efficacy of this combination.

Participants will:

* Take the drugs combination every day for 5 executive days, and 2 days of, in a 28 days cycle, for up to a year.
* Visit the clinic once every 2 weeks for checkups and tests

Conditions

  • Solid Tumors Refractory to Standard Therapy

Interventions

DRUG

Palbociclib

Palbociclib and Sunitinib

DRUG

Sunitinib

Palbociclib and Sunitinib

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • idit Peretz, MD,MBA · Rabin Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-21
Primary Completion
2026-01-01
Completion
2028-01-01
FDA Drug
Yes

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06940349 on ClinicalTrials.gov